Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection.

Toni HertaMagdalena HahnMelanie Maier Janett FischerJohannes NiemeyerMario HönemannAlbrecht BöhligFlorian GerhardtAaron SchindlerJonas SchumacherThomas Berg Johannes Wiegand Florian van Boemmel

Published in: Pathogens (Basel, Switzerland) (2022)

The first real-life data of the approved dosage of 2 mg of BLV in combination with TDF confirm the safety, tolerability, and efficacy of the registrational trial MYR202 for a treatment period of 24 weeks and beyond.

Keyphrases

hepatitis b virus
open label
clinical trial
study protocol
phase iii
electronic health record
phase ii
big data
machine learning
gestational age
liver fibrosis
artificial intelligence
replacement therapy
data analysis